Sign up
Pharma Capital

Destiny Pharma to push ahead with next-generation antibiotic after $15mln IPO

Destiny Pharma plc (LON:DEST), only the second biotech float this year, is bringing through a next-generation antibiotic.

Chief executive Neil Clark tells Proactive The bulk of the £15mln they raised will go towards funding a phase IIb clinical trial on XF-73 for the prevention of post-surgical staphylococcus aureus infections, including the deadly MRSA.


View full DEST profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.